Clovis Oncology Inc.

1.70-0.0400-2.30%Vol 26.45M1Y Perf -72.34%
Jun 24th, 2022 16:00 DELAYED
BID1.67 ASK1.72
Open1.66 Previous Close1.74
Pre-Market- After-Market1.71
 - -  0.01 0.59%
Target Price
3.00 
Analyst Rating
Hold 3.33
Potential %
76.47 
Finscreener Ranking
★★+     47.17
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     67.72
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
18.44 
Earnings Rating
Strong Buy
Market Cap244.59M 
Earnings Date
3rd Aug 2022
Alpha-0.02 Standard Deviation0.54
Beta1.61 

Today's Price Range

1.661.91

52W Range

0.58106.65

5 Year PE Ratio Range

-4.40-1.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
44.07%
1 Month
153.92%
3 Months
6.25%
6 Months
-46.37%
1 Year
-72.34%
3 Years
-87.33%
5 Years
-98.21%
10 Years
-92.28%

TickerPriceChg.Chg.%
CLVS1.70-0.0400-2.30
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
ProfitabilityValueIndustryS&P 500US Markets
73.40
-155.90
-150.30
-339.80
-
RevenueValueIndustryS&P 500US Markets
144.95M
1.01
7.89
57.17
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.43-0.44-2.33
Q04 2021-0.60-0.4918.33
Q03 2021-0.48-0.56-16.67
Q02 2021-0.57-0.61-7.02
Q01 2021-0.72-0.6411.11
Q04 2020-0.76-0.742.63
Q03 2020-1.01-0.8911.88
Q02 2020-1.02-1.11-8.82
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.4116.33Positive
9/2022 QR-0.446.38Positive
12/2022 FY-1.66-3.75Negative
12/2023 FY-0.839.78Positive
Next Report Date3rd Aug 2022
Estimated EPS Next Report-0.41
Estimates Count3
EPS Growth Next 5 Years %40.20
Volume Overview
Volume26.45M
Shares Outstanding143.88K
Shares Float141.10M
Trades Count42.02K
Dollar Volume46.51M
Avg. Volume25.10M
Avg. Weekly Volume44.39M
Avg. Monthly Volume15.57M
Avg. Quarterly Volume15.34M

Clovis Oncology Inc. (NASDAQ: CLVS) stock closed at 1.7 per share at the end of the most recent trading day (a -2.3% change compared to the prior day closing price) with a volume of 26.45M shares and market capitalization of 244.59M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Clovis Oncology Inc. CEO is Patrick J. Mahaffy.

The one-year performance of Clovis Oncology Inc. stock is -72.34%, while year-to-date (YTD) performance is -37.27%. CLVS stock has a five-year performance of -98.21%. Its 52-week range is between 0.581 and 6.65, which gives CLVS stock a 52-week price range ratio of 18.44%

Clovis Oncology Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 7.70, a price-to-sale (PS) ratio of 0.69, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -53.29%, a ROC of -18.45% and a ROE of 100.94%. The company’s profit margin is -%, its EBITDA margin is -150.30%, and its revenue ttm is $144.95 Million , which makes it $1.01 revenue per share.

Of the last four earnings reports from Clovis Oncology Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Clovis Oncology Inc.’s next earnings report date is 03rd Aug 2022.

The consensus rating of Wall Street analysts for Clovis Oncology Inc. is Hold (3.33), with a target price of $3, which is +76.47% compared to the current price. The earnings rating for Clovis Oncology Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Clovis Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Clovis Oncology Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.72, ATR14 : 0.26, CCI20 : 173.42, Chaikin Money Flow : -0.24, MACD : 0.13, Money Flow Index : 84.87, ROC : 133.93, RSI : 69.48, STOCH (14,3) : 61.52, STOCH RSI : 0.88, UO : 49.71, Williams %R : -38.48), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Clovis Oncology Inc. in the last 12-months were: Daniel W. Muehl (Option Excercise at a value of $0), Daniel W. Muehl (Sold 25 468 shares of value $62 465 ), Gillian C. Ivers-Read (Option Excercise at a value of $0), Gillian C. Ivers-Read (Sold 25 259 shares of value $56 800 ), Lindsey Rolfe (Option Excercise at a value of $0), Lindsey Rolfe (Sold 24 253 shares of value $59 471 ), Paul Edward Gross (Option Excercise at a value of $0), Paul Edward Gross (Sold 27 871 shares of value $64 008 ), Thomas C. Harding (Option Excercise at a value of $0), Thomas C. Harding (Sold 13 654 shares of value $31 535 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
1 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
1 (33.33 %)
Moderate Sell
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.33
Hold
3.33
Hold
2.67

Clovis Oncology Inc.

Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.

CEO: Patrick J. Mahaffy

Telephone: +1 303 625-5000

Address: 5500 Flatiron Parkway, Boulder 80301, CO, US

Number of employees: 429

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

53%47%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

TipRanks News for CLVS

Tue, 14 Jun 2022 14:05 GMT Analysts Conflicted on These Healthcare Names: Clovis Oncology (CLVS) and OrthoPediatrics (KIDS)

- TipRanks. All rights reserved.

Mon, 06 Jun 2022 15:55 GMT Clovis Oncology (CLVS) Gets a Hold Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Fri, 01 Apr 2022 12:04 GMT Clovis Jumps 22.4% on Positive Data for Rubraca

- TipRanks. All rights reserved.

News

Stocktwits